| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | - | - | - |
| Operating Income | - | - | - |
| Ordinary Income | ¥3.53B | ¥0.96B | +267.5% |
| Net Income | ¥2.43B | ¥0.65B | +274.3% |
| ROE | 8.3% | 2.2% | - |
Both ordinary income and net income more than tripled year on year, resulting in a quarter of significant profit growth driven by improvements in underwriting and investment income. Revenue (ordinary income from external customers) was ¥21.91B (¥18.24B in the previous year, +20.1%), ordinary income was ¥3.53B (¥0.96B in the previous year, +267.5%), and net income was ¥2.43B (¥0.65B in the previous year, +274.3%). In addition to the improvement in the loss ratio in the core Non-Life Insurance Business, the recognition of ¥2.00B in gains on sales of securities boosted ordinary income. Growth in underlying earnings power, excluding the temporary contribution from investment income, can also be confirmed.
【Revenue】Revenue was ¥21.91B, an increase of +20.1% year on year. The core Non-Life Insurance Business drove overall growth, with revenue of ¥19.51B (+20.9%), accounting for approximately 89% of total revenue. The Veterinary Hospital Operations Business (¥0.82B, +20.2%) and Health Innovation Business (¥0.17B, +37.9%) also achieved strong growth, while the Internet Services for Pets Business declined to ¥0.58B (-2.7%).
【Profit and Loss】Ordinary income increased significantly to ¥3.53B (¥0.96B in the previous year). The operating margin improved substantially to 16.1% from 5.3% in the previous year. Segment profit in the Non-Life Insurance Business was ¥3.73B (¥1.00B in the previous year), almost single-handedly driving consolidated profit, while the combined ratio improved to approximately 93.8%, confirming improved profitability. Meanwhile, the Veterinary Hospital Operations Business turned to a loss of ¥0.19B, compared with a profit of ¥0.06B in the previous year, and the deficit in the Health Innovation Business also widened. The growth in ordinary income was also significantly supported by ¥2.00B in gains on sales of securities, and attention is required because this includes a temporary factor related to investment income. Extraordinary losses were minimal at ¥0.01B, and the ordinary income-to-net income difference was primarily the ordinary difference arising from income taxes and other taxes (¥1.09B, effective tax rate of approximately 30.9%). In conclusion, both revenue and profit increased.
The Non-Life Insurance Business remained the core of consolidated earnings, with revenue of ¥19.51B (+20.9%) and segment profit of ¥3.73B (¥1.00B in the previous year), resulting in a highly concentrated earnings structure. The Internet Services for Pets Business recorded revenue of ¥0.58B (-2.7%) and profit of ¥0.05B (¥0.08B in the previous year), representing a decline in profit. The Veterinary Hospital Operations Business expanded to revenue of ¥0.82B (+20.2%), but its profit turned to a loss of ¥0.19B. The Health Innovation Business grew to revenue of ¥0.17B (+37.9%), while its loss widened to ¥0.07B from the previous year. Although peripheral businesses are generally growing in revenue, monetization remains an issue, and consolidated profit continues to be highly dependent on the Non-Life Insurance Business.
【Profitability】The operating margin improved substantially to 16.1% (5.3% in the previous year), while the net profit margin improved to 11.1% (3.6% in the previous year), and ROE was 8.3%. 【Cash Quality】Ordinary income includes ¥2.00B in gains on sales of securities and therefore incorporates a temporary boost from investment income; it must be evaluated separately from underlying underwriting earnings power. 【Investment Efficiency】Net assets were ¥29.26B against total assets of ¥75.74B, indicating that asset efficiency improved slightly from the previous year. 【Financial Soundness】The equity ratio rose slightly to 38.6% (37.9% in the previous year), and the interest burden on ¥5.0B in outstanding bonds was minimal. Valuation differences on other securities deteriorated to -¥9.64B (-¥1.61B in the previous year), indicating increased capital sensitivity to market fluctuations.
Although the cash flow statement has not been disclosed, an analysis of fund movements based on changes in the balance sheet shows that cash and deposits declined to ¥10.59B from ¥13.39B in the previous year, while securities increased to ¥43.32B (¥42.63B in the previous year), suggesting that a portion of funds may have been invested in securities. Retained earnings accumulated to ¥18.00B (¥16.23B in the previous year), with the period’s profit growth contributing to stronger internal reserves. Treasury stock increased to ¥1.49B (¥1.00B in the previous year), indicating that share repurchases are also progressing as a use of funds under the capital policy. Although insurance policy reserves declined slightly to ¥28.81B (¥29.08B in the previous year), unpaid claims increased to ¥4.35B (¥4.12B in the previous year), indicating that funding needs related to insurance liabilities are being managed generally stably.
Current-period ordinary income includes stable underwriting income and interest and dividend income, as well as the temporary factor of ¥2.00B in gains on sales of securities. These gains are equivalent to approximately 9% of ordinary revenue. The loss ratio was favorable at approximately 63% on an estimated basis, and unpaid claims increased by ¥0.23B from the previous year, suggesting that the soundness of reserving has been maintained. Extraordinary losses were minimal at ¥0.01B, and the difference between ordinary income and net income was primarily attributable to the tax burden, with the impact of temporary factors limited. Meanwhile, comprehensive income of ¥1.47B was below net income of ¥2.43B, and the deterioration in valuation differences on other securities (-¥0.96B) was a negative factor for capital. This indicates a divergence between the pace of net income growth and the pace of capital growth.
Against the full-year company plan of ordinary income of ¥5.00B, net income of ¥3.25B, and EPS of ¥44.43, progress as of Q1 was 70.6% for ordinary income and 74.9% for net income, substantially exceeding the simple one-quarter progress benchmark of 25%. This above-plan progress is largely attributable to the recognition of the temporary factor of ¥2.00B in gains on sales of securities. As investment income normalizes from the second half onward, the pace of progress may slow. Neither the earnings forecast nor the dividend forecast was revised during the quarter, and the company has maintained its current plan.
The full-year dividend forecast is ¥13.5 per share, with no revision from the previous year. Based on the company’s net income plan of ¥3.25B and the average number of shares outstanding during the period, the payout ratio is approximately 30% on an estimated basis. Given the substantial internal reserves represented by retained earnings of ¥18.00B, there are no significant concerns regarding dividend sustainability. Treasury stock increased to ¥1.49B from ¥1.00B in the same period of the previous year, suggesting that shareholder returns through share repurchases are also progressing.
Temporary nature of investment income: Gains on sales of securities of ¥2.00B made a significant contribution to current-period ordinary income of ¥3.53B, and the 70.6% full-year progress rate includes an element that cannot be explained by underlying earnings alone. If gains on sales of securities normalize toward the second half, the pace of progress may slow.
Business portfolio concentration risk: While the Non-Life Insurance Business accounts for approximately 89% of revenue and nearly all segment profit, the Veterinary Hospital Operations Business (-¥0.19B) and Health Innovation Business (-¥0.07B) continue to operate at losses, with the deficits expanding. The earnings structure therefore remains dependent on a single business.
Capital fluctuation risk: Valuation differences on other securities deteriorated to -¥9.64B (-¥1.61B in the previous year), and comprehensive income of ¥1.47B was below net income of ¥2.43B. The impact of market price fluctuations on capital stability requires continuous monitoring.
No industry benchmark data available
Source: Company research
The operating margin improved substantially to 16.1% (5.3% in the previous year) due to the improvement in the loss ratio in the Non-Life Insurance Business, confirming an improvement in underlying underwriting earnings power.
Both ordinary income and net income exceeded 70% of their respective full-year targets, but the significant contribution from the temporary factor of ¥2.00B in gains on sales of securities makes it important to normalize progress when interpreting the financial results.
Continued losses in the Veterinary Hospital Operations Business and Health Innovation Business indicate that consolidated profit remains concentrated in the Non-Life Insurance Business. Monetization of peripheral businesses will be an important structural focus going forward.
This report is an automatically generated financial-results analysis document created by AI based on XBRL financial-results summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed financial-results data. Investment decisions should be made at your own discretion and responsibility, after consulting with a professional as necessary.
---End of Report---